Plant Name: Polyalthia longifolia var. pendula
Taxonomic Information:
Plant ID: NPO30067.1
Plant Latin Name: Polyalthia longifolia var. pendula
Taxonomy Genus: Monoon
Taxonomy Family: Annonaceae
Plant External Links:
NCBI TaxonomyDB:
235806
Plant-of-the-World-Online:
77123022-1
Used in Medicines:
Unknown.
Geographical Distribution:
Bangladesh; India; Cambodia; Trinidad and Tobago; Sri Lanka; Cameroon
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD5; DRD3; DRD4; DRD1; DRD2; | |
| F3; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Small molecule receptor (family A GPCR) | DRD5 | Dopamine D5 receptor | P21918 | CHEMBL1850 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.252E-11 | 1.817E-08 | DRD1, DRD2, DRD3, DRD4 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 9.320E-10 | 6.765E-07 | DRD2, DRD3, DRD4 |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 1.997E-09 | 1.208E-06 | DRD1, DRD3, DRD5 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 1.997E-09 | 1.208E-06 | DRD2, DRD3, DRD4 |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 2.745E-09 | 1.533E-06 | DRD2, DRD3, DRD4 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 4.757E-09 | 2.409E-06 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 4.757E-09 | 2.409E-06 | DRD1, DRD2, DRD5 |
| BP | GO:0065007; biological regulation | GO:0006874; cellular calcium ion homeostasis | 1.717E-08 | 7.479E-06 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 2.942E-08 | 1.144E-05 | DRD2, DRD3, DRD4 |
| BP | GO:0007610; behavior | GO:0046960; sensitization | 8.041E-08 | 2.636E-05 | DRD1, DRD5 |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 8.232E-08 | 2.636E-05 | DRD2, DRD3, DRD4 |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 8.232E-08 | 2.636E-05 | DRD1, DRD2, DRD5 |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 1.903E-07 | 5.313E-05 | DRD2, DRD3, DRD5 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 2.412E-07 | 6.179E-05 | DRD2, DRD3 |
| BP | GO:0023052; signaling | GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission | 2.412E-07 | 6.179E-05 | DRD2, DRD4 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.698E-07 | 6.676E-05 | DRD1, DRD2, DRD3, DRD4, DRD5, F3 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 2.865E-07 | 6.901E-05 | DRD1, DRD2, DRD3 |
| MF | GO:0060089; molecular transducer activity | GO:0001588; dopamine neurotransmitter receptor activity, coupled via Gs | 4.823E-07 | 9.983E-05 | DRD1, DRD5 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 8.038E-07 | 1.483E-04 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 8.038E-07 | 1.483E-04 | DRD2, DRD3 |
| BP | Unclassified; | GO:0032415; regulation of sodium:proton antiporter activity | 1.205E-06 | 2.007E-04 | DRD3, DRD4 |
| BP | GO:0051179; localization | GO:0002028; regulation of sodium ion transport | 1.516E-06 | 2.427E-04 | DRD2, DRD3, DRD4 |
| CC | GO:0044422; organelle part | GO:0060170; ciliary membrane | 1.516E-06 | 2.427E-04 | DRD1, DRD2, DRD5 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 3.614E-06 | 5.282E-04 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 4.417E-06 | 6.328E-04 | DRD2, DRD3 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 4.417E-06 | 6.328E-04 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0050709; negative regulation of protein secretion | 4.730E-06 | 6.688E-04 | DRD2, DRD3, DRD4 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 5.300E-06 | 7.445E-04 | DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 6.262E-06 | 8.631E-04 | DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0048149; behavioral response to ethanol | 7.305E-06 | 9.942E-04 | DRD2, DRD4 |
| BP | GO:0023052; signaling | GO:0060292; long term synaptic depression | 9.631E-06 | 1.256E-03 | DRD1, DRD5 |
| BP | GO:0051179; localization | GO:1901386; negative regulation of voltage-gated calcium channel activity | 1.091E-05 | 1.398E-03 | DRD2, DRD4 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.156E-05 | 1.473E-03 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| BP | GO:0009987; cellular process | GO:0019226; transmission of nerve impulse | 1.228E-05 | 1.537E-03 | DRD1, DRD5 |
| BP | GO:0008152; metabolic process | GO:0042053; regulation of dopamine metabolic process | 1.372E-05 | 1.678E-03 | DRD1, DRD4 |
| BP | GO:0032501; multicellular organismal process | GO:0045187; regulation of circadian sleep/wake cycle, sleep | 1.372E-05 | 1.678E-03 | DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0007617; mating behavior | 1.372E-05 | 1.678E-03 | DRD1, DRD5 |
| BP | GO:0008152; metabolic process | GO:0031325; positive regulation of cellular metabolic process | 1.537E-05 | 1.850E-03 | DRD1, DRD2, DRD3, DRD4, DRD5, F3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.403E-05 | 2.772E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0007628; adult walking behavior | 2.813E-05 | 3.032E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 3.029E-05 | 3.201E-03 | DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0001662; behavioral fear response | 3.484E-05 | 3.480E-03 | DRD1, DRD4 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 3.724E-05 | 3.653E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 3.972E-05 | 3.777E-03 | DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0071870; cellular response to catecholamine stimulus | 4.491E-05 | 4.233E-03 | DRD1, DRD5 |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 5.329E-05 | 4.856E-03 | DRD1, DRD5 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 6.087E-05 | 5.379E-03 | DRD2, DRD3, DRD4 |
| BP | GO:0008152; metabolic process | GO:0030819; positive regulation of cAMP biosynthetic process | 1.018E-04 | 8.463E-03 | DRD1, DRD5 |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 1.185E-04 | 9.704E-03 | DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.447E-16 | 3.753E-12 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 1.761E-14 | 9.585E-11 | DRD1, DRD2, DRD3, DRD4, DRD5 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 6.164E-11 | 8.013E-10 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.917E-09 | 1.896E-08 | DRD1, DRD2, DRD3, DRD4, DRD5 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.898E-05 | 8.226E-05 | DRD1, DRD2, DRD5 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 8.765E-05 | 2.849E-04 | DRD1, DRD2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.838E-04 | 7.380E-04 | DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.180E-03 | 1.917E-03 | DRD1, DRD5 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 7.370E-04 | 1.597E-03 | DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 1.167E-03 | 1.917E-03 | DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 1.993E-02 | 2.879E-02 | DRD1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04610 | Complement and coagulation cascades | 2.347E-02 | 3.051E-02 | F3 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD5; DRD1; DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | DRD5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
